{
    "ticker": "ONMD",
    "name": "OncoOne, Inc.",
    "description": "OncoOne, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for cancer treatment. Founded in 2015 and headquartered in Boulder, Colorado, OncoOne is pioneering the development of novel therapies aimed at targeting the underlying mechanisms of cancer. The company's lead candidate, OncoOne-OD, is a proprietary drug designed to target the oncogene called alpha-2-macroglobulin (A2M), which plays a crucial role in cancer progression and metastasis. By inhibiting A2M, OncoOne aims to disrupt the cancer cell's ability to thrive and spread, offering a new potential treatment pathway for patients with various types of cancer. The company is committed to advancing its clinical programs and is actively engaged in partnerships and collaborations to enhance its research and development efforts. OncoOne's mission is to provide groundbreaking therapies that improve patient outcomes and quality of life in the fight against cancer. With a strong emphasis on scientific rigor and innovation, OncoOne is poised to make a significant impact in the biotechnology landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boulder, Colorado, USA",
    "founded": "2015",
    "website": "https://www.oncoone.com",
    "ceo": "Dr. L. C. (Lynn) A. G. (Lynn) Brant",
    "social_media": {
        "twitter": "https://twitter.com/OncoOneInc",
        "linkedin": "https://www.linkedin.com/company/oncoone/"
    },
    "investor_relations": "https://www.oncoone.com/investors",
    "key_executives": [
        {
            "name": "Dr. L. C. (Lynn) A. G. (Lynn) Brant",
            "position": "CEO"
        },
        {
            "name": "Dr. Kelly M. McCarty",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OncoOne-OD"
            ]
        }
    ],
    "seo": {
        "meta_title": "OncoOne, Inc. | Innovative Cancer Therapeutics",
        "meta_description": "Discover OncoOne, Inc., a clinical-stage biotechnology company developing novel therapeutics for cancer treatment. Explore their innovative approach and pipeline.",
        "keywords": [
            "OncoOne",
            "Cancer Treatment",
            "Biotechnology",
            "Pharmaceuticals",
            "OncoOne-OD"
        ]
    },
    "faq": [
        {
            "question": "What is OncoOne known for?",
            "answer": "OncoOne is known for developing innovative therapeutics targeting cancer, particularly its lead product OncoOne-OD."
        },
        {
            "question": "Who is the CEO of OncoOne?",
            "answer": "Dr. L. C. (Lynn) A. G. (Lynn) Brant is the CEO of OncoOne, Inc."
        },
        {
            "question": "Where is OncoOne headquartered?",
            "answer": "OncoOne is headquartered in Boulder, Colorado, USA."
        },
        {
            "question": "What is OncoOne's main product?",
            "answer": "OncoOne's main product is OncoOne-OD, a therapeutic targeting the oncogene alpha-2-macroglobulin."
        },
        {
            "question": "When was OncoOne founded?",
            "answer": "OncoOne was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "NVS",
        "BMY",
        "GILD"
    ],
    "related_stocks": [
        "PFE",
        "MRNA",
        "JNJ",
        "ABBV"
    ]
}